Watch for Ensifentrine (Ohtuvayre) for COPD
You’ll get questions about ensifentrine (Ohtuvayre), a new nebulized med for COPD maintenance therapy in adults.
It’s the first dual phosphodiesterase 3 (PDE3) AND phosphodiesterase 4 (PDE4) inhibitor...that bronchodilates and reduces inflammation.
Oral roflumilast (Daliresp) for severe COPD only inhibits PDE4.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote